Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma: a Prospective Cohort Study
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
306 participants
Aug 23, 2024
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to learn about the Effects of neoadjuvant therapy with carboplatin, paclitaxel combined with anti-PD-1 drugs on cognitive function in patients with resectable head and neck squamous cell carcinoma: a prospective cohort study
Eligibility
Inclusion Criteria3
- : The patient was diagnosed with head and neck squamous cell carcinoma (stage I-IVA), without treatment, and planned to undergo only surgical treatment or surgical treatment + chemotherapy and immunotherapy.
- : Can speak Chinese and have certain reading and writing skills
- : Healthy group: Dental inpatients with non-oral cancer, no history of neurological diseases, and no previous history of malignant tumors
Exclusion Criteria7
- : Brain tumor, brain injury, or stroke at baseline or during follow-up
- : A history of stroke or a medical condition that puts you at high risk for future dementia or recurrence
- : Active mental illness or active narcotic drug use, including using alcohol more than 4 times per day or more than 4 times per week
- : Neurocognitive diseases that affect cognitive function, such as Parkinson's disease or Alzheimer's disease
- : History of drug-associated encephalopathy or brain infection
- : Patients who change their treatment plan during treatment
- : Patients who are currently taking or have taken antidepressants
Interventions
Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Standard of care
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06576180